FDA Reclassifications In Brief
This article was originally published in The Gray Sheet
Executive Summary
Digital mammography: FDA 1proposes May 30 to downclassify full field digital mammography systems from Class III to Class II, following the 2006 recommendation of its Radiological Devices Panel (2"The Gray Sheet" May 29, 2006, p. 6). The agency also released a special controls 3draft guidance outlining proposed electrical safety and physical laboratory 510(k) testing requirements. Comments on the proposed reclassification and draft guidance are due Aug. 29
You may also be interested in...
Guidance Needed On Internal Tissue Adhesives, FDA And Industry Agree
Based on discussions at a recent workshop, FDA sees "multiple opportunities for guidance" on internal tissue adhesives, an agency official said.
Guidance Needed On Internal Tissue Adhesives, FDA And Industry Agree
Based on discussions at a recent workshop, FDA sees "multiple opportunities for guidance" on internal tissue adhesives, an agency official said.
Digital Mammography Firms Decry Clinical Trial Provisions In Draft Guidance
Digital mammography systems are on the verge of being downclassified to 510(k) status, but imaging firms say the clinical trial requirements proposed in FDA's draft "special controls" guidance for the systems are costly, unnecessary and overly burdensome